Diaverum, a global leader in renal care acquired by the M42 in 2023, announced plans to start operations in Abu Dhabi and Al Ain, bringing advanced technological solutions and personalised patient care to renal patients in the UAE.
As the largest provider of renal care in Saudi Arabia with 40 clinics in 33 cities and 1,300 healthcare professionals, the move marks Diaverum’s efforts to expand its footprint in the Gulf region.
The company’s UAE plans envisage delivering a variety of treatment options, including hemodialysis, holiday dialysis and home dialysis.
Additionally, it will leverage M42’s global patient care platform, along with its digital and integrated healthcare capabilities, to disrupt traditional renal care models and shift towards precision and preventive approaches for longer, healthier lives.
Ziyad Kabli, Chief Operating Officer for Diaverum Middle East and Africa, said the company’s entry into the UAE marks a major step forward in its mission to transform renal care globally and expand its reach in the Middle East.
“By blending our high standards of care and expertise in AI-driven, personalised renal treatment with M42’s comprehensive patient care platform and solid local presence, we are excited to shape a future-focused renal care landscape in the UAE, which prioritises innovation, quality and sustainability,” he said.
Chronic kidney disease (CKD) is an escalating global health challenge, affecting approximately 10 per cent of the world’s population and is projected to be the fifth leading cause of death by 2040.
This represents a particular challenge in the UAE, where an estimated over 16 per cent of adults suffer from diabetes, a leading cause of kidney failure.
The country also faces challenges related to lifestyle factors such as obesity, which can contribute to the rise in CKD.
Follow us on
